Pharmacological Management of Non-REM Parasomnia



Note: Treatments noted in this pathway are **IMOC Amber 2 category** – initiation and minimum 3 months' supply by the sleep centre (specialising in Non-REM parasomnia). GPs are **not** expected to initiate these treatments but may be asked to take on prescribing in line with IMOC recommendations (patients will have individual management plans in place).

Diagnosis of:

Non-REM Parasomnia

All patients:

- > Reinforce good sleep hygiene
- > Identify and treat potential triggering sleep pathology

On-going recommendation of treatment regimen.

Consider referral to Complex Sleep Service for non-pharmacological therapy.

Referral made by specialist physician within sleep centre.

First line therapy (specialist initiation):

Melatonin M/R <u>2-6mg nocte</u>

(Melatonin is supplied as 2mg modified release tablets)

Review by specialist in 3-6 months

Regular follow up in clinic or via telephone by the sleep pharmacist between consultant appointments.

No significant improvement or adverse reaction to melatonin:

Clonazepam <u>0.25-2mg nocte</u> (specialist initiation) (may be used first line in cases where parasomnia behaviours place patient or others at risk of harm)

Review by specialist in 3-6 months

Regular follow up in clinic or via telephone by the sleep pharmacist between consultant appointments.

No significant improvement or adverse reaction to clonazepam:

- 1. Stop ineffective/not tolerated treatment
- 2. Consider combination therapy (melatonin & clonazepam)

Consider **third line monotherapy** options as appropriate **(specialist initiation)**: *(decision of agent will be based on patient symptoms and relevant factors)*

- Alternative BZRA*
 - o Zopiclone 3.75-15mg nocte
- > Tricyclic antidepressants
 - o Imipramine 50-300mg nocte
 - Clomipramine 10-75mg nocte
- > SSRI antidepressants:
 - Fluoxetine 20-60mg daily
 - o Sertraline 25-150mg daily

Review by specialist in 3-6 months

Regular follow up in clinic or via telephone by the sleep pharmacist between consultant appointments.

*BZRA= Benzodiazepine receptor agonists

Approval date: March 2023 Review date: March 2025